{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:19:51Z","timestamp":1790191191091,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s10928-018-9568-y","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T08:19:16Z","timestamp":1517905156000},"page":"127-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["How to mathematically optimize drug regimens using optimal control"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2185-2785","authenticated-orcid":false,"given":"Helen","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"key":"9568_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi JA, Grabowski HG, Hansen RA (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47:20\u201333","journal-title":"J Health Econ"},{"key":"9568_CR2","unstructured":"Sorger PK, Allerheiligen SRB, Abernethy DR, Altman RB, Brouwer KLR, Califano A, D\u2019Argenio DZ, Iyengar R, Jusko WJ, Lalonde R, Lauffenburger DA, Shoichet B, Stevens JL, Subramaniam S, Van der Graaf P, Vicini P, Ward R (2011) Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. An NIH White Paper by the QSP Workshop Group. National Institutes of Health website. https:\/\/www.nigms.nih.gov\/training\/documents\/systemspharmawpsorger2011.pdf . Accessed 4 Jan 2018"},{"key":"9568_CR3","unstructured":"Obituary: Colin Day (2012) Santa Barbara Independent website. http:\/\/www.independent.com\/obits\/2012\/feb\/21\/colin-day\/ . Accessed 4 June 2017"},{"issue":"1","key":"9568_CR4","first-page":"127","volume":"70","author":"JH Goldie","year":"1986","unstructured":"Goldie JH, Coldman AJ (1986) Application of theoretical models to chemotherapy protocol design. Cancer Treat Rep 70(1):127\u201331","journal-title":"Cancer Treat Rep"},{"issue":"8","key":"9568_CR5","first-page":"3876","volume":"46","author":"RS Day","year":"1986","unstructured":"Day RS (1986) Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 46(8):3876\u20133885","journal-title":"Cancer Res"},{"issue":"4","key":"9568_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00285-003-0246-2","volume":"48","author":"EA Gaffney","year":"2004","unstructured":"Gaffney EA (2004) The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling. J Math Biol 48(4):375\u2013422","journal-title":"J Math Biol"},{"issue":"2","key":"9568_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jtbi.2008.12.006","volume":"257","author":"HC Monro","year":"2009","unstructured":"Monro HC, Gaffney EA (2009) Modelling chemotherapy resistance in palliation and failed cure. J Theor Biol 257(2):292\u2013302","journal-title":"J Theor Biol"},{"issue":"4","key":"9568_CR8","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1200\/JCO.1998.16.4.1358","volume":"16","author":"A Goldhirsch","year":"1998","unstructured":"Goldhirsch A, Coates AS, Colleoni M, Castiglione-Gertsch M, Gelber RD (1998) Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group. J Clin Oncol 16(4):1358\u20131362","journal-title":"J Clin Oncol"},{"issue":"6 Suppl 15","key":"9568_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.seminoncol.2004.11.024","volume":"31","author":"FM Muggia","year":"2004","unstructured":"Muggia FM (2004) Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer. Semin Oncol 31(6 Suppl 15):19\u201324","journal-title":"Semin Oncol"},{"issue":"24","key":"9568_CR10","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/jnci\/djq409","volume":"102","author":"L Bonilla","year":"2010","unstructured":"Bonilla L, Ben-Aharon I, Vidal L, Gafter-Gvili A, Leibovici L, Stemmer SM (2010) Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 102(24):1845\u20131854","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"9568_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.critrevonc.2011.04.010","volume":"81","author":"GH Lyman","year":"2012","unstructured":"Lyman GH, Barron RL, Natoli JL, Miller RM (2012) Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. Crit Rev Oncol Hematol 81(3):296\u2013308","journal-title":"Crit Rev Oncol Hematol"},{"key":"9568_CR12","doi-asserted-by":"crossref","unstructured":"Karlsson P, Cole BF, Price KN, Gelber RD, Coates AS, Goldhirsch A, Castiglione M, Colleoni M, Gruber G; International Breast Cancer Study Group (2016) Timing of radiation therapy and chemotherapy after breast-conserving surgery for node-positive breast cancer: Long-term results from International Breast Cancer Study Group Trials VI and VII. Int J Radiat Oncol Biol Phys 96(2):273\u2013279","DOI":"10.1016\/j.ijrobp.2016.06.2448"},{"key":"9568_CR13","unstructured":"The Voice of the Patient Report: Human Immunodeficiency Virus (HIV) Patient-Focused Drug Development and HIV Cure Research (2014) US Food and Drug Administration (FDA) website. https:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM389379.pdf . Accessed 2 Jan 2018"},{"issue":"2","key":"9568_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3934\/mbe.2005.2.363","volume":"2","author":"H Moore","year":"2005","unstructured":"Moore H, Gu W (2005) A mathematical model for treatment-resitant mutations of HIV. Math Biosci Eng 2(2):363\u2013380","journal-title":"Math Biosci Eng"},{"key":"9568_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1090\/conm\/410\/07725","volume":"410","author":"W Gu","year":"2006","unstructured":"Gu W, Moore H (2006) Optimal therapy regimens for treatment-resistant mutations of HIV. Contemp Math 410:139\u2013152","journal-title":"Contemp Math"},{"key":"9568_CR16","unstructured":"Imatinib prescribing information (2008) FDA website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021588s024lbl.pdf . Accessed 29 May 2017"},{"key":"9568_CR17","unstructured":"Dasatinib Prescribing Information (2010) FDA website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021986s7s8lbl.pdf . Accessed 29 May 2017"},{"key":"9568_CR18","unstructured":"Nilotinib Prescribing Information (2007) FDA website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/022068lbl.pdf . Accessed 29 May 2017."},{"key":"9568_CR19","unstructured":"Bosutinib Prescribing Information (2012) FDA website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203341lbl.pdf . Accessed 29 May 2017"},{"key":"9568_CR20","unstructured":"Ponatinib Prescribing Information (2012) FDA website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203469lbl.pdf . Accessed 29 May 2017"},{"issue":"2","key":"9568_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3934\/mbe.2011.8.289","volume":"8","author":"NL Komarova","year":"2011","unstructured":"Komarova NL (2011) Mathematical modeling of cyclic treatments of chronic myeloid leukemia. Math Biosci Eng 8(2):289\u2013306","journal-title":"Math Biosci Eng"},{"key":"9568_CR22","unstructured":"A phase 1B study to investigate the safety and preliminary efficacy for the combination of dasatinib plus nivolumab in patients with chronic myeloid leukemia (2013) ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02011945 . Accessed 4 June 2017"},{"key":"9568_CR23","unstructured":"Moore H, Strauss L, Ledzewicz U (submitted) Optimization of combination therapy for chronic myeloid leukemia with dosing constraints"},{"issue":"1","key":"9568_CR24","first-page":"331","volume":"23","author":"U Ledzewicz","year":"2018","unstructured":"Ledzewicz U, Moore H (2018) Optimal control applied to a generalized Michaelis-Menten model of CML therapy. Discret Contin Dyn Syst Ser B 23(1):331\u2013346","journal-title":"Discret Contin Dyn Syst Ser B"},{"issue":"10","key":"9568_CR25","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/app6100291","volume":"6","author":"U Ledzewicz","year":"2016","unstructured":"Ledzewicz U, Moore H (2016) Dynamical systems properties of a mathematical model for the treatment of CML. Appl Sci 6(10):291. https:\/\/doi.org\/10.3390\/app6100291","journal-title":"Appl Sci"},{"key":"9568_CR26","unstructured":"Moore H (2016) Mathematical Optimization of Combination Therapy Regimens Webinar, Rosa & Co. website. http:\/\/www.rosaandco.com\/webinars\/2016\/mathematical-optimization-of-combination-therapy-regimens . Accessed 4 June 2017"},{"key":"9568_CR27","volume-title":"Mathematics and war","author":"RV Gamkrelidze","year":"2003","unstructured":"Gamkrelidze RV (2003) Discovery of the maximum principle in optimal control. In: Boos-Bavnbek B, Hoyrup J (eds) Mathematics and war. Birkhauser, Basel"},{"key":"9568_CR28","unstructured":"Melfi T (2016) Hidden figures [Motion Picture]. United States: 20th Century Fox"},{"key":"9568_CR29","first-page":"7","volume":"110","author":"VG Boltyanskii","year":"1956","unstructured":"Boltyanskii VG, Gamkrelidze RV, Pontryagin LS (1956) On the theory of optimal processes. Dokl Akad Nauk SSSR 110:7\u201310 (in Russian)","journal-title":"Dokl Akad Nauk SSSR"},{"key":"9568_CR30","first-page":"1070","volume":"119","author":"VG Boltyanskii","year":"1958","unstructured":"Boltyanskii VG (1958) The maximum principle in the theory of optimal processes. Dokl Akad Nauk SSSR 119:1070\u20131073 (in Russian)","journal-title":"Dokl Akad Nauk SSSR"},{"key":"9568_CR31","first-page":"223","volume":"123","author":"RV Gamkrelidze","year":"1958","unstructured":"Gamkrelidze RV (1958) On the general theory of optimal processes. Dokl Akad Nauk SSSR 123:223\u2013226 (in Russian)","journal-title":"Dokl Akad Nauk SSSR"},{"key":"9568_CR32","first-page":"3","volume":"14","author":"LS Pontryagin","year":"1959","unstructured":"Pontryagin LS (1959) Optimal control processes II. Uspekhi Matematicheskikh Nauk 14:3\u201320 (in Russian)","journal-title":"Uspekhi Matematicheskikh Nauk"},{"key":"9568_CR33","first-page":"3","volume":"24","author":"VG Boltyanskii","year":"1960","unstructured":"Boltyanskii VG, Gamkrelidze RV, Pontryagin LS (1960) The theory of optimal processes I. The maximum principle. Izvestija Akademii Nauk SSSR Ser Mat 24:3\u201342 (in Russian)","journal-title":"Izvestija Akademii Nauk SSSR Ser Mat"},{"key":"9568_CR34","first-page":"973","volume":"38","author":"HJ Pesch","year":"2009","unstructured":"Pesch HJ, Plail M (2009) The maximum principle of optimal control: a history of ingenious ideas and missed opportunities. Control Cybern 38:973\u2013995","journal-title":"Control Cybern"},{"key":"9568_CR35","unstructured":"Hestenes MR (1950) A general problem in the calculus of variations with applications to the paths of least time. Research Memorandum No. 100, RAND Corp, Santa Monica, CA, USA"},{"key":"9568_CR36","unstructured":"Isaacs RP (1951) Games of pursuit. Paper No. P-257, RAND Corp, Santa Monica, CA, USA"},{"key":"9568_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1090\/S0002-9904-1954-09848-8","volume":"60","author":"RE Bellman","year":"1954","unstructured":"Bellman RE (1954) The theory of dynamic programming. Bull AMS 60:503\u2013516","journal-title":"Bull AMS"},{"issue":"4","key":"9568_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1073\/pnas.40.4.231","volume":"40","author":"RE Bellman","year":"1954","unstructured":"Bellman RE (1954) Dynamic programming and a new formalism in the calculus of variations. Proc Natl Acad Sci USA 40(4):231\u2013235","journal-title":"Proc Natl Acad Sci USA"},{"key":"9568_CR39","unstructured":"National Defense Education Act (n.d.) United States House of Representatives website. http:\/\/history.house.gov\/HouseRecord\/Detail\/15032436195 . Accessed 2 Jan 2018"},{"key":"9568_CR40","unstructured":"Where the Future Becomes Now (n.d.) Defense Advanced Research Projects Agency website. https:\/\/www.darpa.mil\/about-us\/darpa-history-and-timeline . Accessed 2 Jan 2018"},{"key":"9568_CR41","unstructured":"NASA History Overview (n.d.) National Aerospace and Science Administration website. https:\/\/www.nasa.gov\/content\/nasa-history-overview . Accessed 2 Jan 2018"},{"issue":"1","key":"9568_CR42","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2307\/3003143","volume":"4","author":"RC Merton","year":"1973","unstructured":"Merton RC (1973) Theory of rational option pricing. Bell J Econ Manag Sci 4(1):141\u2013183","journal-title":"Bell J Econ Manag Sci"},{"issue":"3","key":"9568_CR43","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1086\/260062","volume":"81","author":"F Black","year":"1973","unstructured":"Black F, Scholes M (1973) The pricing of options and corporate liabilities. J Polit Econ 81(3):637\u2013654","journal-title":"J Polit Econ"},{"key":"9568_CR44","doi-asserted-by":"publisher","DOI":"10.7551\/mitpress\/9780262134606.001.0001","volume-title":"An engine, not a camera: how financial models shape markets","author":"D MacKenzie","year":"2006","unstructured":"MacKenzie D (2006) An engine, not a camera: how financial models shape markets. MIT Press, Cambridge"},{"key":"9568_CR45","unstructured":"The Prize in Economic Sciences 1997-Press Release (1997) NobelPrize.org website. http:\/\/www.nobelprize.org\/nobel_prizes\/economic-sciences\/laureates\/1997\/press.html . Accessed 4 June 2017"},{"key":"9568_CR46","volume-title":"Applications of optimal control theory in biomedicine","author":"GW Swan","year":"1984","unstructured":"Swan GW (1984) Applications of optimal control theory in biomedicine. Marcel Dekker Inc., New York"},{"key":"9568_CR47","volume-title":"Optimal control of drug administration in cancer chemotherapy","author":"RB Martin","year":"1994","unstructured":"Martin RB, Teo KL (1994) Optimal control of drug administration in cancer chemotherapy. World Scientific Publishing Co., Singapore"},{"key":"9568_CR48","doi-asserted-by":"crossref","DOI":"10.1201\/9781420011418","volume-title":"Optimal control applied to biological models","author":"S Lenhart","year":"2007","unstructured":"Lenhart S, Workman JT (2007) Optimal control applied to biological models. Chapman & Hall\/CRC, Boca Raton"},{"key":"9568_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-2972-6","volume-title":"Optimal control for mathematical models of cancer therapies","author":"H Sch\u00e4ttler","year":"2015","unstructured":"Sch\u00e4ttler H, Ledzewicz U (2015) Optimal control for mathematical models of cancer therapies. Springer, New York"},{"key":"9568_CR50","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1002\/psp4.20","volume":"4","author":"MC Peterson","year":"2015","unstructured":"Peterson MC, Riggs MM (2015) FDA advisory meeting clinical pharmacology review utilizes a quantitative systems pharmacology (QSP) model: a watershed moment? CPT Pharmacomet Syst Pharmacol 4:e20","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"9568_CR51","unstructured":"FDA approves first automated insulin delivery device for type 1 diabetes-Press Release (2016) FDA website. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm522974.htm . Accessed 4 June 2017"},{"key":"9568_CR52","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jtbi.2003.11.024","volume":"227","author":"H Moore","year":"2004","unstructured":"Moore H, Li NK (2004) A mathematical model of chronic myelogenous leukemia (CML) and T cell interaction. J Theor Biol 227:513\u2013523","journal-title":"J Theor Biol"},{"key":"9568_CR53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.mbs.2007.05.003","volume":"210","author":"S Nanda","year":"2007","unstructured":"Nanda S, Moore H, Lenhart S (2007) Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math Biosci 210:143\u2013156","journal-title":"Math Biosci"},{"key":"9568_CR54","volume-title":"Foundations of decision analysis","author":"RA Howard","year":"2015","unstructured":"Howard RA, Abbas AE (2015) Foundations of decision analysis. Pearson Education, London"},{"issue":"6","key":"9568_CR55","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00158-003-0368-6","volume":"26","author":"R Marler","year":"2004","unstructured":"Marler R, Arora J (2004) Survey of multi-objective optimization methods for engineering. Struct Multidiscip Optim 26(6):369\u2013395","journal-title":"Struct Multidiscip Optim"},{"key":"9568_CR56","volume-title":"Classical mechanics","author":"JR Taylor","year":"2005","unstructured":"Taylor JR (2005) Classical mechanics. University Science Books, Sausalito"},{"issue":"3","key":"9568_CR57","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1517\/17425250902787616","volume":"5","author":"E Shudo","year":"2009","unstructured":"Shudo E, Ribeiro RM, Perelson AS (2009) Modeling hepatitis C virus kinetics under therapy using pharmacokinetic and pharmacodynamic information. Expert Opin Drug Metab Toxicol 5(3):321\u2013332","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"9568_CR58","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3934\/mbe.2009.6.93","volume":"6","author":"SR Pope","year":"2009","unstructured":"Pope SR, Ellwein LM, Zapata CL, Novak V, Kelley CT, Olufsen MS (2009) Estimation and identification of parameters in a lumped cerebrovascular model. Math Biosci Eng 6(1):93\u2013115","journal-title":"Math Biosci Eng"},{"issue":"1","key":"9568_CR59","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00285-012-0535-8","volume":"67","author":"MS Olufsen","year":"2013","unstructured":"Olufsen MS, Ottesen JT (2013) A practical approach to parameter estimation applied to model predicting heart rate regulation. J Math Biol 67(1):39\u201368","journal-title":"J Math Biol"},{"key":"9568_CR60","volume-title":"Design of robust control systems: from classical to modern practical approaches","author":"MJ Sidi","year":"2001","unstructured":"Sidi MJ (2001) Design of robust control systems: from classical to modern practical approaches. Krieger Pub Co, Malabar"},{"key":"9568_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-6380-7","volume-title":"Deterministic and stochastic optimal control","author":"WH Fleming","year":"1975","unstructured":"Fleming WH, Rishel RW (1975) Deterministic and stochastic optimal control. Springer, New York"},{"issue":"10","key":"9568_CR62","doi-asserted-by":"publisher","first-page":"38503861","DOI":"10.1002\/jps.21682","volume":"98","author":"I Mahmood","year":"2009","unstructured":"Mahmood I (2009) Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci 98(10):38503861","journal-title":"J Pharm Sci"},{"issue":"3","key":"9568_CR63","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/BF02462912","volume":"39","author":"GW Swan","year":"1977","unstructured":"Swan GW, Vincent TL (1977) Optimal control analysis in the chemotherapy of IgG multiple myeloma. Bull Math Biol 39(3):317\u2013337","journal-title":"Bull Math Biol"},{"issue":"3","key":"9568_CR64","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1006\/cbmr.2000.1540","volume":"33","author":"A Iliadis","year":"2000","unstructured":"Iliadis A, Barbolosi D (2000) Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model. Comput Biomed Res 33(3):211\u2013226","journal-title":"Comput Biomed Res"},{"key":"9568_CR65","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1038\/psp.2013.65","volume":"3","author":"XY Zhang","year":"2014","unstructured":"Zhang XY, Birtwistle MR, Gallo JM (2014) A general network pharmacodynamic model-based design pipeline for customized cancer therapy applied to the VEGFR pathway. CPT Pharmacomet Syst Pharmacol 3:e92","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"7","key":"9568_CR66","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s002850050076","volume":"35","author":"D Kirschner","year":"1997","unstructured":"Kirschner D, Lenhart S, Serbin S (1997) Optimal control of the chemotherapy of HIV. J Math Biol 35(7):775\u2013792","journal-title":"J Math Biol"},{"key":"9568_CR67","volume-title":"Dynamic optimization: the calculus of variations and optimal control in economics and management","author":"MI Kamien","year":"1991","unstructured":"Kamien MI, Schwartz NL (1991) Dynamic optimization: the calculus of variations and optimal control in economics and management. Elsevier Science, Amsterdam"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-018-9568-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9568-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9568-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T13:49:13Z","timestamp":1603806553000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-018-9568-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["9568"],"URL":"https:\/\/doi.org\/10.1007\/s10928-018-9568-y","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"5 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}